A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin’s lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists

2016 ◽  
Vol 104 (3) ◽  
pp. 378-383 ◽  
Author(s):  
Tsutomu Takahashi ◽  
Satoshi Kumanomidou ◽  
Saki Takami ◽  
Takahiro Okada ◽  
Koji Adachi ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Hodgkin’S Lymphoma ◽  
Nausea And Vomiting ◽  
Hodgkin's Lymphoma ◽  
Receptor Antagonists ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Chop Therapy

Autoimmune disease-associated non-Hodgkin’s lymphoma—a large retrospective study from China

2018 ◽  
Vol 98 (2) ◽  
pp. 445-455 ◽  
Author(s):  
Shaoxuan Hu ◽  
Daobin Zhou ◽  
Yongji Wu ◽  
Yongqiang Zhao ◽  
Shujie Wang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Autoimmune Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large Retrospective Study

scholarly journals Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation

2021 ◽  
Author(s):  
Nicola Di Renzo ◽  
Maurizio Musso ◽  
Rosanna Scimè ◽  
Alessandra Cupri ◽  
Tommasina Perrone ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Complete Response ◽  
Nausea And Vomiting ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Purpose Prevention of chemotherapy-induced nausea and vomiting (CINV) is particularly challenging for patients receiving highly emetogenic preparative regimens before autologous stem cell transplantation (ASCT) due to the daily and continuous emetogenic stimulus of the multiple day chemotherapy. While studies have shown effective prevention of CINV during the conditioning phase with NK1 receptor antagonist (NK1RA)-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT. Methods This multicenter, open-label, phase IIa study evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin’s lymphoma. Eighty-one patients participated. Results Response rates were 77.8% for complete response (no emesis and no rescue use), 72.8% for complete control (complete response and no more than mild nausea), 86.4% for no emesis, and 82.7% for no rescue use during the overall phase (duration of chemomobilization through 48 h after). NEPA was well tolerated with no treatment-related adverse events reported. Conclusion NEPA, administered with a simplified every-other-day schedule, show to be very effective in preventing CINV in patients at high risk of CINV undergoing to chemomobilization of hematopoietic stem cells prior to ASCT.

Sign in / Sign up

Export Citation Format

Share Document